Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2022 | An insight into the CADENZA study: pivekimab sunirine in patients with R/R BPDCN

Naveen Pemmaraju • 27 Aug 2022
Texas MPN Workshop 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Myeloproliferative Neoplasms Rare Diseases Antibodies Pivekimab sunirine
CADENZA

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the CADENZA study (NCT03386513) which is evaluating the use of pivekimab sunirine in patients with relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), and further highlights the promise of CD123-targeted therapy in this field.This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:13
Current and emerging treatment options for patients with MF who are ineligible for ruxolitinib
Claire Harrison • 29 Apr 2024
0:52
The unmet needs that remain for patients with systemic mastocytosis
Deepti Radia • 29 Apr 2024
2:12
The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals